Search research articles
Contact Us
Filters
Showing results (41-50 of 70) with videos related to
Page
of 7
Sort By:
ESMO Open
|
March 29, 2023
Clinical risk factors for ascites in metastatic pancreatic cancer
J M Berger, A Alany, R Puhr, et al.
Journal of Thrombosis and Haemostasis : JTH
|
April 21, 2018
Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism
P Mir Seyed Nazari, J Riedl, M Preusser, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 3, 2020
Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up
B Jordan, A Margulies, F Cardoso, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
March 1, 2014
Prognostic significance of Ki67 proliferation index, HIF1 alpha index and microvascular density in patients with non-small cell lung cancer brain metastases
A S Berghoff, A Ilhan-Mutlu, A Wöhrer, et al.
AJNR. American Journal of Neuroradiology
|
August 16, 2013
Arterial spin-labeling assessment of normalized vascular intratumoral signal intensity as a predictor of histologic grade of astrocytic neoplasms
J Furtner, V Schöpf, K Schewzow, et al.
British Journal of Cancer
|
May 14, 2009
FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo
D Cejka, C Kuntner, M Preusser, et al.
ESMO Open
|
February 15, 2021
Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases
A Steindl, D Alpar, G Heller, et al.
British Journal of Cancer
|
October 11, 2012
Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors
A S Berghoff, Z Bago-Horvath, A Ilhan-Mutlu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 9, 2017
EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours
E Le Rhun, M Weller, D Brandsma, et al.
ESMO Open
|
June 27, 2022
Development of an alarm symptom-based risk prediction score for localized oesophagogastric adenocarcinoma (VIOLA score)
H C Puhr, R Puhr, D A Kuchling, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 70) with videos related to
Sort By:
Page
of 7
ESMO Open
|
March 29, 2023
Clinical risk factors for ascites in metastatic pancreatic cancer
J M Berger, A Alany, R Puhr, et al.
Journal of Thrombosis and Haemostasis : JTH
|
April 21, 2018
Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism
P Mir Seyed Nazari, J Riedl, M Preusser, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 3, 2020
Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up
B Jordan, A Margulies, F Cardoso, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
March 1, 2014
Prognostic significance of Ki67 proliferation index, HIF1 alpha index and microvascular density in patients with non-small cell lung cancer brain metastases
A S Berghoff, A Ilhan-Mutlu, A Wöhrer, et al.
AJNR. American Journal of Neuroradiology
|
August 16, 2013
Arterial spin-labeling assessment of normalized vascular intratumoral signal intensity as a predictor of histologic grade of astrocytic neoplasms
J Furtner, V Schöpf, K Schewzow, et al.
British Journal of Cancer
|
May 14, 2009
FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo
D Cejka, C Kuntner, M Preusser, et al.
ESMO Open
|
February 15, 2021
Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases
A Steindl, D Alpar, G Heller, et al.
British Journal of Cancer
|
October 11, 2012
Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors
A S Berghoff, Z Bago-Horvath, A Ilhan-Mutlu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 9, 2017
EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours
E Le Rhun, M Weller, D Brandsma, et al.
ESMO Open
|
June 27, 2022
Development of an alarm symptom-based risk prediction score for localized oesophagogastric adenocarcinoma (VIOLA score)
H C Puhr, R Puhr, D A Kuchling, et al.
Page
of 7